期刊
ONCOTARGET
卷 6, 期 27, 页码 23720-23734出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4690
关键词
patient derived xenograft; platinum resistance; tumor spheres; cancer initiating cells; beta-catenin
资金
- Visual Sciences Research Center (VSRC) Core Grant [P30-EY11373]
- Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center [P30CA043703]
- Case Comprehensive Cancer Center [P30 CA043703]
- Colleen's Dream Foundation
Resistance to platinum-based chemotherapy is the major barrier to treating epithelial ovarian cancer. To improve patient outcomes, it is critical to identify the underlying mechanisms that promote platinum resistance. Emerging evidence supports the concept that platinum-based therapies are able to eliminate the bulk of differentiated cancer cells, but are unable to eliminate cancer initiating cells (CIC). To date, the relevant pathways that regulate ovarian CICs remain elusive. Several correlative studies have shown that Wnt/beta-catenin pathway activation is associated with poor outcomes in patients with high-grade serous ovarian cancer (HGSOC). However, the functional relevance of these findings remain to be delineated. We have uncovered that Wnt/beta-catenin pathway activation is a critical driver of HGSOC chemotherapy resistance, and targeted inhibition of this pathway, which eliminates CICs, represents a novel and effective treatment for chemoresistant HGSOC. Here we show that Wnt/beta-catenin signaling is activated in ovarian CICs, and targeted inhibition of beta-catenin potently sensitized cells to cisplatin and decreased CIC tumor sphere formation. Furthermore, the Wnt/beta-catenin specific inhibitor iCG-001 potently sensitized cells to cisplatin and decreased stem-cell frequency in platinum resistant cells. Taken together, our data is the first report providing evidence that the Wnt/beta-catenin signaling pathway maintains stem-like properties and drug resistance of primary HGSOC PDX derived platinum resistant models, and therapeutic targeting of this pathway with iCG-001/PRI-724, which has been shown to be well tolerated in Phase I trials, may be an effective treatment option.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据